← SynDRA
OMARIGLIPTIN
SynDRA canonical compound SYN0031621 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Primary target(s) | DPP4 |
|---|
| Mechanism of action | dipeptidyl peptidase inhibitor |
|---|
| Indication | diabetes mellitus |
|---|
| Disease area | endocrinology |
|---|
All known targets
Mechanisms of action (all sources)
- DPP4 inhibitor
- dipeptidyl peptidase inhibitor
- DPP4 MODULATOR
Cross-references
Synonyms
- marizev
- Mk-3102
- MK3102
- Omarigliptine
- Omarigliptina
- MK-3102
- CVP59Q4JE1
- omarigliptinum
- RefChem:856762
- DTXCID1076169
- MFCD22573261
- Omarigliptin (MK-3102)
- UNII-CVP59Q4JE1
- C17H20F2N4O3S
- Omarigliptin [USAN]
- Omarigliptin [USAN:INN]
- Omarigliptin (Standard)
- MK-3102Omarigliptin?
- OMARIGLIPTIN [MI]
- OMARIGLIPTIN [INN]
- OMARIGLIPTIN [JAN]
- OMARIGLIPTIN [WHO-DD]
- SCHEMBL827590
- GTPL8402
- Omarigliptin (JAN/USAN/INN)
- orb1305710
- SCHEMBL30291226
- EX-A395
- CHEBI:134735
- MKMPWKUAHLTIBJ-ISTRZQFTSA-N
- GLXC-90340
- BDBM50003020
- HY-15981R
- NSC802900
- s8565
- AKOS025289528
- CCG-268634
- CS-3948
Look up OMARIGLIPTIN in the interactive SynDRA portal →